Reduction of imatinib absorption after gastric bypass surgery
Authors:
- 6 December 2010
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (2) , 310-313
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Outcomes of sleeve gastrectomy for morbid obesity: A safe and effective procedure?International Journal of Surgery, 2010
- A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling TimesTherapeutic Drug Monitoring, 2009
- Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient with Chronic Myeloid LeukemiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal TumorsJournal of Clinical Oncology, 2009
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 2009
- European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorBlood, 2008
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood, 2008
- The Duodenal Switch Operation for Morbid ObesitySurgical Clinics of North America, 2005
- Clinical Pharmacokinetics of ImatinibClinical Pharmacokinetics, 2005
- Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia PatientsJournal of Clinical Oncology, 2004